{
    "2020-09-29": [
        [
            {
                "time": "2023-10-01",
                "original_text": "Regeneron Pharmaceutical Posts Positive Initial Data On Its Covid-19 Treatment",
                "features": {
                    "keywords": [
                        "Regeneron",
                        "Pharmaceutical",
                        "Positive",
                        "Initial",
                        "Data",
                        "Covid-19",
                        "Treatment"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2023-10-01",
                "original_text": "3 Reasons Growth Investors Will Love Lilly (LLY)",
                "features": {
                    "keywords": [
                        "Growth",
                        "Investors",
                        "Lilly",
                        "LLY"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-10-01",
                "original_text": "Why Eli Lilly (LLY) is a Top Dividend Stock for Your Portfolio",
                "features": {
                    "keywords": [
                        "Eli",
                        "Lilly",
                        "LLY",
                        "Dividend",
                        "Stock",
                        "Portfolio"
                    ],
                    "sentiment_score": 0.65,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-10-01",
                "original_text": "Is Eli Lilly and (LLY) Stock Outpacing Its Medical Peers This Year?",
                "features": {
                    "keywords": [
                        "Eli",
                        "Lilly",
                        "LLY",
                        "Stock",
                        "Outpacing",
                        "Medical",
                        "Peers"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-10-01",
                "original_text": "Eli Lilly (NYSE:LLY) Has Compensated Shareholders With A Respectable 98% Return On Their Investment",
                "features": {
                    "keywords": [
                        "Eli",
                        "Lilly",
                        "LLY",
                        "Shareholders",
                        "Return",
                        "Investment"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}